Patients More Adherent to Generic Statins
Low-cost generic statins improve compliance and clinical outcomes compared to their brand-name counterparts. Those are the findings of a recent study of Medicare beneficiaries who were on the cholesterol-lowering medications. Researchers reviewed the records of 90,000 statin users of which 93% took a generic and 7% took a branded version. The mean age was 75 years and about 60% were women. The average out-of-pocket cost was $10 for the generic statin vs $48 for the brand-name product. Adherence (as measured by proportion of days covered) was 77% in the generic group and 71% in the brand name group (P < 0.001). The generic group also saw an 8% reduction in the composite outcome of hospitalization for acute coronary syndrome, stroke, or all-cause mortality compared to the brand-name group (HR, 0.92; 95%CI, 0.86-0.99). The authors conclude that “compared to those initiating brand-name statins, patients initiating generic statins were more likely to adhere and had a lower rate of a composite clinical outcome.” (Ann Intern Med 2014;161:400-407). An accompanying editorial points out that this study was looking at generic vs brand-name drugs “but the operating factor for patients is affordability.”
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.